Ekuqaleni evezwe ngo-1973 ngu-Ralph Steinman kanye no-Zanvil Cohn, amaseli e-dendritic (DCs) anomsebenzi obalulekile wokuphazamisa ukusabela okungenakuthinteka kwangaphakathi kanye nokukhuthaza ukusabela okuguquguqukayo kokuzivikela komzimba. Kusukela kulelo phuzu kuya phambili, ama-DC abhekwa njengamaseli anamandla kakhulu e-antigen-displaying (APCs), avame ukubizwa ngokuthi "i-Nature's adjuvant," eklanyelwe ukuqalisa ukusabela okukholelwayo nokungakwazi ukukhumbula. Mayelana nokuvikela nokuphatha ama-antigens ukuze angeniswe kuma-T cell, ama-DC anomkhawulo ovamile futhi aveza inani elingavamile lama-athomu e-costimulatory noma ahlanganisayo anquma ukuqaliswa okuvikelekile noma ukungabaza1. Cishe eminyakeni engama-40 ngemva kwalokho, lapho uMklomelo KaNobel Wezokwelapha noma WePhysiology uklonyeliswa uRalph Steinman ngo-2011 ngokudalula kwakhe lawa mangqamuzana omzimba abalulekile emvelo, ukubaluleka kwama-DCs kwabonwa.
Lokhu immunotherapy treatment helps the body battle cancer cells with its own defense mechanism. Dendritic cell therapy is often used when regular therapies have not been effective. As of late, this treatment was proposed in India and multiple patients were relieved under the supervision of the renowned Oncologist with empowering results. Be that as it may, there are common drugs that have been developed over decades for most forms of isisu. Usage of these drugs is administered and combined with unsusceptible care, since it is realized that tumor cells weakened by chemotherapy or radiation are considerably easier to decimate with invulnerable cells than with flawless tumor cells.
Uhlobo lomdlavuza olulashwa nge-dendritic cell based immunotherapy treatment
- Umdlavuza wesikhumba
- Umdlavuza wezinso
- Umdlavuza wesibeletho
- Umdlavuza we-Pancreatic
- Umdlavuza weColon
- Umdlavuza we-Ovarian
- Umdlavuza wendlala
Ukwelashwa komdlavuza wesigaba IV
Dendritic cell based immunotherapy treatment has proved to be quite a success specially with no hope stage IV cancer treatment. Patients specially on stage IV cancer can try and go for dendritic cell based immunotherapy in cancer treatment.
Izibhedlela ze-dendritic cell based immunotherapy treatment eNdiya
- I-LDG India Ltd, iGurugram
- I-APAC Biotech, Noida
- Ucwaningo lwamaseli e-Dendritic, eNew Delhi
Izindleko zokwelashwa kwe-dendritic cell based immunotherapy eNdiya
Izindleko zokwelashwa kwe-dendritic cell based immunotherapy zingahluka $ 8000 USD - $ 15,000 USD kuye ngesigaba somdlavuza kanye nokwelapha udokotela kanye nesibhedlela.
